ETF Series Solutions Trust Range Cancer Therapeutics ETF

CNCR

市值 US$704萬

Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?

Medical breakthroughs are occurring constantly, but they often get lost in the news headlines unless they directly impact our lives. I wanted to take a moment to highlight a few recent medical breakthroughs and developments and explore a few ways to get actionable exposure to them with ETFs.

SFYX, CNCR, FXN and DIV are included in this Analyst Blog.

Low-priced ETFs could be attractive for investors as these enable them to buy more shares instead of just a handful of higher-priced shares for the same amount.

Wall Street roars back from its biggest weekly losses of the year, driven by bargain hunting and looming Fed rate cuts.

Wall Street was upbeat last week on Fed rate cut hopes.

After a three-day rout, Wall Street staged a solid comeback as investors bought beaten-down stocks and recession fears eased. To tap the beaten-down prices, we have highlighted five ETFs from different corners that have declined over the past week and have a solid Zacks ETF Rank.

Wall Street offered a mixed performance last week.

Wall Street was moderately upbeat last week with the S&P 500, the Dow Jones and the Nasdaq gaining 0.87%, 1.6% and 0.3%, respectively. However, the small-cap index – the Russell 2000 – has advanced 6% as consumer inflation print came in at cooler-than-expected.

Last week was a busy one for ETFs, with nine new ETFs launching on the first day of the week alone. Calamos, Innovator, AllianzIM, Direxion, Global X and ProShares were among the issuers rolling out new funds.